Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

TearLab Corp (NASDAQ:TEAR)

0.7478
Delayed Data
As of May 02
 -0.0322 / -4.13%
Today’s Change
0.60
Today|||52-Week Range
3.03
-46.20%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Medical Specialties
MARKET CAP
$26.4M

Company Description

TearLab Corp. engages in the development and marketing of lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing disease markers in tears at the point-of-care. Its products include TearLab Osmolarity System consisting TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. The company was founded by Benjamin D. Sullivan in 1996 and is headquartered in San Diego, CA.

Contact Information

TearLab Corp.
9980 Huennekens Street
San Diego California 92121
P:(858) 455-6006
Investor Relations:
(647) 872-4849

Employees

Shareholders

Other institutional33.75%
Individual stakeholders14.04%
Mutual fund holders10.83%

Top Executives

Joseph JensenPresident, CEO, COO & Director
Wes BrazellChief Financial Officer
Benjamin D. SullivanChief Scientific Officer
Michael A. LempChief Medical Officer
David Craig EldridgeVP-Clinical Affairs & Professional Development